Abingworth's BioVentures VII fund closes at $315M, exceeding target

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe.

Abingworth's therapeutic interests for BioVentures VII include next-generation cell therapies, antivirals and anti-infectives, Managing Partner Kurt von Emster told BioCentury...